Aptose Biosciences Inc. (APTO)

Aptose Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	13.62	15.59	14.51	19.46	26.48	10.02
Research & Development	34.4	36.77	28.09	45.99	29.29	16.84
Operating Expenses	48.02	52.36	42.6	65.45	55.77	26.86
Operating Income	-48.02	-52.36	-42.6	-65.45	-55.77	-26.86
Other Expense / Income	-0.85	-1.15	-0.78	-0.09	-0.53	-0.58
Pretax Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Net Income	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28
Shares Outstanding (Basic)	13	7	6	6	5	3
Shares Outstanding (Diluted)	13	7	6	6	5	3
Shares Change	112.82%	9.82%	3.57%	8.86%	63.15%	50.22%
EPS (Basic)	-6.20	-7.58	-6.80	-10.95	-10.05	-7.80
EPS (Diluted)	-6.20	-7.58	-6.80	-10.95	-10.05	-7.80
Free Cash Flow	-45.09	-44.62	-32.35	-43.52	-33.97	-21.66
Free Cash Flow Per Share	-3.43	-6.61	-5.26	-7.33	-6.23	-6.48
EBITDA	-46.73	-50.74	-41.3	-64.73	-54.62	-25.66
Depreciation & Amortization	0.44	0.47	0.53	0.62	0.61	0.61
EBIT	-47.17	-51.21	-41.82	-65.35	-55.24	-26.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).